{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:25:32Z","timestamp":1767921932153,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>BRAF V600E\/K mutations are significant drivers of metastatic melanoma, and therapies that selectively target these mutations have significantly improved patient long-term survival. Emerging evidence suggests that tumors harboring BRAF non-V600E\/K mutations are susceptible to MEK-targeting therapies, but these mutations are not always assessed in clinical workup. To assess whether patient stratification for targeted therapy can be improved, we characterized the prevalence and nature of BRAF non-V600E\/K mutations in a cohort of patients diagnosed with metastatic melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We extracted DNA from 99 specimens collected between June 2019 and September 2021. The samples were analyzed using next-generation sequencing to identify mutations in BRAF exon 15 and to assess their susceptibility to targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven percent of patient specimens contained BRAF non-V600E\/K mutations in exon 15. Of the mutations identified, all have prior evidence of susceptibility to targeted MEK therapies. Among those patients, less than half received targeted MEK therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Next-generation sequencing is a sensitive platform for profiling BRAF exon 15 mutations that cannot be detected by other techniques. Our results support the routine sequencing of BRAF exon 15 to improve patient stratification for therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf122","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:59:07Z","timestamp":1760097547000},"page":"841-844","source":"Crossref","is-referenced-by-count":0,"title":["Routine sequencing of\n                    <i>BRAF<\/i>\n                    exon 15 improves therapeutic stratification for metastatic melanoma"],"prefix":"10.1093","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4462","authenticated-orcid":false,"given":"Yi Fan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospitals Cleveland Medical Center , Cleveland, OH,","place":["United States"]},{"name":"Medical Scientist Training Program, Case Western Reserve University School of Medicine , Cleveland, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshna","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kaiser Permanente Oakland Medical Center , Oakland, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica E","family":"Sigel","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospitals Cleveland Medical Center , Cleveland, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5051-717X","authenticated-orcid":false,"given":"Navid","family":"Sadri","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospitals Cleveland Medical Center , Cleveland, OH,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"2026010814424303600_aqaf122-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"Cancer J Clin"},{"key":"2026010814424303600_aqaf122-B2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjd.21649","article-title":"The effect of screening on melanoma incidence and biopsy rates","volume":"187","author":"Whiteman","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026010814424303600_aqaf122-B3","doi-asserted-by":"crossref","first-page":"e2245269","DOI":"10.1001\/jamanetworkopen.2022.45269","article-title":"Melanoma treatments and mortality rate trends in the US, 1975 to 2019","volume":"5","author":"Kahlon","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026010814424303600_aqaf122-B4","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010814424303600_aqaf122-B5","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1158\/1078-0432.CCR-17-0980","article-title":"MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases","volume":"23","author":"Bai","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026010814424303600_aqaf122-B6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"2026010814424303600_aqaf122-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2407-14-13","article-title":"Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations","volume":"14","author":"Ihle","year":"2014","journal-title":"BMC Cancer"},{"key":"2026010814424303600_aqaf122-B8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"2026010814424303600_aqaf122-B9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/jclinpath-2012-201345","article-title":"The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations","volume":"66","author":"Ponti","year":"2013","journal-title":"J Clin Pathol"},{"key":"2026010814424303600_aqaf122-B10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"Klein","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026010814424303600_aqaf122-B11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40164-017-0067-4","article-title":"Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months","volume":"6","author":"Marconcini","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"2026010814424303600_aqaf122-B12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/CMR.0000000000000099","article-title":"Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma","volume":"24","author":"Bowyer","year":"2014","journal-title":"Melanoma Res"},{"key":"2026010814424303600_aqaf122-B13","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted therapy in advanced melanoma with rare BRAF mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026010814424303600_aqaf122-B14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmolb.2020.00113","article-title":"The current state of molecular testing in the BRAF-mutated melanoma landscape","volume":"7","author":"Vanni","year":"2020","journal-title":"Front Mol Biosci"},{"key":"2026010814424303600_aqaf122-B15","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"2026010814424303600_aqaf122-B16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"2026010814424303600_aqaf122-B17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"2026010814424303600_aqaf122-B18","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"2026010814424303600_aqaf122-B19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/onco.13795","article-title":"Efficacy and safety of trametinib in non-V600 BRAF mutant melanoma: a phase II study","volume":"26","author":"Nebhan","year":"2021","journal-title":"Oncologist"},{"key":"2026010814424303600_aqaf122-B20","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026010814424303600_aqaf122-B21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","article-title":"Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing","volume":"15","author":"Colomba","year":"2013","journal-title":"J Mol Diagn"},{"key":"2026010814424303600_aqaf122-B22","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.5858\/arpa.2011-0505-OA","article-title":"Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma","volume":"136","author":"Anderson","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"2026010814424303600_aqaf122-B23","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1038\/s41598-021-88391-5","article-title":"High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens","volume":"11","author":"Cheng","year":"2021","journal-title":"Sci Rep"},{"key":"2026010814424303600_aqaf122-B24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00428-018-2393-2","article-title":"Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma","volume":"473","author":"Zhu","year":"2018","journal-title":"Virchows Arch"},{"key":"2026010814424303600_aqaf122-B25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/cancers16061215","article-title":"Mutations in the serine\/threonine kinase BRAF: oncogenic drivers in solid tumors","volume":"16","author":"Roa","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Am J Clin Pathol"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/6\/841\/65469169\/aqaf122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/6\/841\/65469169\/aqaf122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:42:49Z","timestamp":1767901369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/164\/6\/841\/8340178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,22]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf122","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,22]]}}}